

## Livmarli® (maralixibat) – New formulation approval

- On April 14, 2025, <u>Mirum Pharmaceuticals announced</u> the FDA approval of <u>Livmarli (maralixibat)</u> tablets, for the treatment of:
  - Cholestatic pruritus in patients 3 months of age and older with Alagille syndrome (ALGS)
  - Cholestatic pruritus in patients 12 months of age and older with progressive familial intrahepatic cholestasis (PFIC).
- Livmarli tablets are a new formulation of maralixibat. Livmarli is also available as an oral solution (9.5 mg and 19 mg per mL).
- Livmarli tablets can be used for treatment of both ALGS and PFIC in patients weighing 25 kg and above who can swallow tablets. Refer to the drug label for complete dosing and administration recommendations.
- Mirum Pharmaceuticals plans to launch Livmarli tablets in June 2025. Livmarli tablets will be available in 10 mg, 15 mg, 20 mg, and 30 mg strengths.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.